HC Wainwright reiterated their buy rating on shares of Tyme Technologies (NASDAQ:TYME) in a report released on Thursday morning, MarketBeat.com reports. The brokerage currently has a $9.50 price target on the stock, up from their previous price target of $8.00.

A number of other analysts also recently issued reports on TYME. Evercore ISI initiated coverage on shares of Tyme Technologies in a research report on Friday, November 17th. They set an outperform rating and a $7.00 target price for the company. Canaccord Genuity initiated coverage on shares of Tyme Technologies in a research report on Wednesday, January 3rd. They set a buy rating for the company. Finally, BidaskClub raised shares of Tyme Technologies from a sell rating to a hold rating in a research report on Thursday, January 4th.

Shares of Tyme Technologies (NASDAQ TYME) opened at $3.99 on Thursday. The stock has a market cap of $362.70, a P/E ratio of -23.47 and a beta of -0.59. Tyme Technologies has a 1 year low of $2.14 and a 1 year high of $9.50.

In related news, COO Michael Demurjian sold 50,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $3.34, for a total transaction of $167,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Monashee Investment Management LLC acquired a new stake in Tyme Technologies during the 4th quarter worth approximately $128,000. Wells Fargo & Company MN boosted its holdings in Tyme Technologies by 923.9% in the 4th quarter. Wells Fargo & Company MN now owns 29,180 shares of the company’s stock worth $186,000 after acquiring an additional 26,330 shares during the period. Finally, Franklin Street Advisors Inc. NC purchased a new position in Tyme Technologies in the 4th quarter worth approximately $198,000. 2.45% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Tyme Technologies (TYME) Earns “Buy” Rating from HC Wainwright” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://theolympiareport.com/2018/02/12/tyme-technologies-tyme-earns-buy-rating-from-hc-wainwright.html.

About Tyme Technologies

Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.